Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
12/2005
12/15/2005US20050276820 structural modification alters the biological persistence, preferably the biological half-life
12/15/2005DE102004026669A1 Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels Use of a combination of ethinyl estradiol and chlormadinone acetate in the manufacture of a medicament
12/15/2005CA2568641A1 Sustained release composition
12/14/2005EP1604983A1 Receptor antagonist
12/14/2005EP1604682A1 Gonadal function improving agents
12/14/2005EP1604651A1 Transdermal patches and methods for delivering testosterone
12/14/2005EP1603944A1 Amylin aggregation inhibitors and use thereof
12/14/2005EP1603882A2 Urea and thiourea derivatives
12/14/2005EP1450786B1 Isoflavone concentrate and method for production thereof
12/14/2005EP1440052B1 Benzamide derivatives as antagonists of orexin receptors
12/14/2005EP1357870A4 Bioadhesive cell foam film of sustained-release delivery
12/14/2005EP1326858B1 Piperidine compounds as anti-allergic
12/14/2005EP0920504B1 Class e voltage-gated calcium channel antagonist and methods
12/14/2005CN1706838A Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
12/14/2005CN1231483C 8-Azabicyclo [3.,2.1] Oct-2-Ene and-Octane derivatives
12/14/2005CN1231458C Novel aryloxy-alkyl-dialkylamines compound
12/13/2005US6974836 Diamines as modulators of chemokine receptor activity
12/13/2005US6974793 Method for treating primary hyperparathyroid disorders
12/13/2005CA2324403C Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
12/11/2005CA2467769A1 Methods and formulations for testosterone suppression
12/10/2005CA2507847A1 Prostaglandin reductase
12/10/2005CA2507738A1 Modulation of peroxisome proliferator-activated receptors
12/08/2005WO2005115975A1 Arylalkylamines and process for production thereof
12/08/2005WO2005115441A2 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
12/08/2005WO2005115426A1 Drug for ameliorating male climacteric disorder
12/08/2005WO2005115402A1 Use of a combination of ethinyl estradiol and chlormadinone acetate for the production of a medicament
12/08/2005WO2005105148A8 Liquid growth hormone formulation
12/08/2005US20050272936 Imidazolium cxcr3 inhibitors
12/08/2005US20050272817 Dermatological use and a dermatological preparation
12/08/2005US20050272816 3,5,3' -triiodothronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
12/08/2005US20050272801 Isoprenoid pathway inhibitors for stimulating cartilage growth
12/08/2005US20050272789 Triazole-derived kinase inhibitors and uses thereof
12/08/2005US20050272783 Amino acids with affinity for the alpha2delta-protein
12/08/2005US20050272733 1-substituted pyridine-2-ones or 2-substituted pyridazin-3-ones; anticarcinogenic agents for breast and prostate cancer; contraceptives; endometriosis, benign prostatic hypertophy
12/08/2005US20050272718 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
12/08/2005US20050272669 treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole
12/08/2005US20050272638 Improved bioavailability; for oral and intracolonic administration
12/08/2005US20050272148 Method of collecting placental stem cells
12/08/2005US20050271725 Adhesive gel composition for iontophoresis preparation and process for producing the same
12/08/2005DE60017281T2 Nomegestrolacetat und östrogen enthaltende Hormonzusammensetzung und ihre Verwendung Nomegestrol acetate and estrogen hormone-containing composition and its use
12/08/2005CA2569320A1 Drug for ameliorating male climacteric disorder
12/08/2005CA2567056A1 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
12/07/2005EP1602647A1 Novel compound having 4-pyridylalkylthio group as substituent
12/07/2005EP1602370A2 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
12/07/2005EP1601364A2 Method of treating and preventing hyperparathyroidism with vitamin d2 or d4 compounds
12/07/2005EP1601356A1 Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
12/07/2005EP1601251A2 Compounds for the treatment of metabolic disorders
12/07/2005EP1525198B1 Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
12/07/2005EP1246828B1 Benzosulfones with calcium antagonist activity
12/07/2005EP1077928B1 Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
12/07/2005EP1077927B1 Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
12/07/2005EP0981523B1 Cyclic ether vitamin d3 compounds, 1alpha (oh) 3-epi-vitamin d3 compounds and uses thereof
12/07/2005CN1704404A Tricyclic protein kinase inhibitors
12/07/2005CN1230442C GnRh antagonists being modified in positions 5 and 6
12/07/2005CN1230433C Cyclic AMP-specific phosphodiesterase inhibitors
12/07/2005CN1230418C Selective androgen receptor modulators and methods of use thereof
12/07/2005CN1230163C 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens
12/06/2005US6972295 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis
12/06/2005CA2303537C Solid oral dosage form comprising a combination of metformin and glibenclamide
12/01/2005WO2005112949A1 Use of drug combinations for treating insulin resistance
12/01/2005WO2004096118B1 Composition for improving cognition and memory
12/01/2005US20050267206 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
12/01/2005US20050267137 Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof
12/01/2005US20050267133 Pyrazolopyrimidines as kinase inhibitors
12/01/2005US20050267110 Propane-1, 3-dione derivative
12/01/2005US20050267081 Use of a combination of ethinyloestradiol and chlormadinone acetate to produce a pharmaceutical preparation
12/01/2005US20050267038 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005CA2566873A1 Use of drug combinations for treating insulin resistance
12/01/2005CA2565029A1 Immediate release pharmaceutical tablets with height greater than width
12/01/2005CA2564963A1 Steroid prodrugs with androgenic effect
11/2005
11/30/2005EP1599199A2 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
11/30/2005EP1599193A2 Method for treating hypothyroidism
11/30/2005EP1392337B1 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating
11/30/2005EP1313511B1 Testosterone ester formulation for human use
11/30/2005EP1173153B1 Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
11/30/2005EP1156787B1 Oxadiazole compounds and compositions for delivering active agents
11/30/2005EP1144372B1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
11/30/2005EP1109909B1 Grf analogs with increased biological potency
11/30/2005CN1703403A Metabotropic glutamate receptor antagonists
11/30/2005CN1703217A Use of epothilone derivatives for the treatment of hyperparathyroidism
11/30/2005CN1703197A Injectable depot compositions and uses thereof
11/30/2005CN1229390C Peptides that lower blood glucose levels
11/30/2005CN1229381C Macrolides compound
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229335C Nervinolin derivatives
11/30/2005CN1229113C A Pharmaceutical composition for the treatment of autoimmune diseases
11/29/2005US6969729 An indole or benz(g)indole-2,3-dione-3-oxime compounds; therapeutic treatment of respiratory disorders, urogenital disorders, cardiovascular disorders, brain and psychological disorders, gastrointestinal disorders
11/29/2005US6969728 Antiinflammatory agents
11/29/2005US6969724 Compounds
11/29/2005US6969718 17-β hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
11/24/2005WO2005110394A1 Therapeutic agent for diabetes
11/24/2005WO2004091630A8 Remedies for diseases to be applied to eye
11/24/2005US20050261305 Cyclic protein tyrosine kinase inhibitors
11/24/2005US20050261303 e.g. (2R,5S)-4-(3-chloro-4-cyanophenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide; antiandrogenic agent
11/24/2005US20050260750 Process for obtaining mammalian insulin secreting cells in vitro and their uses
11/24/2005US20050260601 Recombinant mutants of rhabdovirus and methods of use thereof
11/24/2005US20050260230 Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins
11/24/2005US20050260211 Drug delivery; delivering a non-cytotoxic therapeutic moiety into nerve cells; nerve growth factor
1 ... 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 ... 290